Paul Blavin
Paul is the co-founder and CEO of Mercy Bioanalytic. He began his career in 1986 as an investment banker with Citibank and Donaldson, Lufkin & Jenrette.
He then served as the President of First Mercury Financial Corporation. Paul is the co-founder and CEO of Mercy BioAnalytics. He then served as the President of First Mercury Financial Corporation, a publicly-traded insurance company. He also co-founded and managed a private investment partnership – PWB Value Partners, L.P. – which began with three investors and $3.2 million under management. Over
Click here to claim your Sponsored Listing.
Category
Website
Address
139A Charles Street #315
Boston
Our novel family of Janus base nanomaterials is based on DNA nanotechnology.
27 Drydock Avenue
Boston, 02210
A next-generation biosecurity platform, by Ginkgo Bioworks.
Boston, 02210
Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for treatment of abnormal mineralization diseases. We are focused on therapies to treat the rare...
Boston, 02109
At Cora Care, we are developing prognostic tools to help pet owners take care of their pets.
Boston, 02210
Innovating to transform the treatment of devastating diseases through intracellular therapeutics.
99 High Street, 30th Floor
Boston, 02110
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, ...
Boston, 02135
NanoView Biosciences is focused on enabling worldwide life science researchers to better understand the biological role of extracellular vesicles, including exosomes and viral vect...
Boston
Welcome to Pronova, we are here to help you care for your pets by pioneering a new standard of care.
121 Seaport Boulevard
Boston, 02210
Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to ...